Potent small molecule Hedgehog agonists induce VEGF expression in vitro
摘要:
Here, we describe the synthesis, SAR studies as well as biological investigations of the known Hedgehog signaling agonist SAG and a small library of its analogues. The SAG and its derivatives were analyzed for their potency to activate the expression of the Hh target gene Gli1 in a reporter gene assay. By analyzing SAR important molecular descriptors for Gill activation have been identified. SAG as well as compound 10c proven to be potent activators of VEGF expression in cultivated dermal fibroblasts. Importantly and in contrast to SAG, derivative 10c displayed no toxicity in concentrations up to 250 mu m. (C) 2012 Elsevier Ltd. All rights reserved.
[EN] 4 - [CYCLOALKYLOXY (HETERO) ARYLAMINO] THIENO [2, 3 - D] PYRIMIDINES HAVING MNKL/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS<br/>[FR] 4-[CYCLOALKYLOXY(HÉTÉRO)ARYLAMINO]THIÉNO[2,3-D]PYRIMIDINES AYANT UNE ACTIVITÉ D'INHIBITION DE MNK1/MNK2 POUR DES COMPOSITIONS PHARMACEUTIQUES
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2011104334A1
公开(公告)日:2011-09-01
The present invention relates to novel thienopyrimidine compounds of general formula (I), pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
4 - [CYCLOALKYLOXY (HETERO) ARYLAMINO]THIENO [2, 3 - D]PYRIMIDINES HAVING MNKL/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS
申请人:Boehringer Ingelheim International GmbH
公开号:EP2539345A1
公开(公告)日:2013-01-02
4-[CYCLOALKYLOXY(HETERO)ARYLAMINO]-THIENO[2,3-D]PYRIMIDINES HAVING MNK1/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS
申请人:Boehringer Ingelheim International GmbH
公开号:EP2539345B1
公开(公告)日:2015-07-22
US8754079B2
申请人:——
公开号:US8754079B2
公开(公告)日:2014-06-17
CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
申请人:LEHMANN-LINTZ Thorsten
公开号:US20110217311A1
公开(公告)日:2011-09-08
The present invention relates to novel thienopyrimidine compounds of general formula
pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2
a
or Mnk2
b
) and/or variants thereof.